Paratek Pharmaceuticals Inc

Paratek Pharmaceuticals — Transcept Pharmaceuticals — Investor Presentation (September 2011)

29 slides from Paratek Pharmaceuticals's investor presentation, Sep 19, 2011

  1. Slide 1: A specialty pharmaceutical company focused on neuroscience

    Exhibit 99.1 A specialty pharmaceutical company focused on the development and commercialization of proprietary products to address important therapeutic needs in the field of neuroscience September 2011

  2. Slide 2: Forward looking statements

    Forward looking statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this presentation are forward-looking statements. Examples of such statements include our expectat

  3. Slide 3: Transcept: preparing for Intermezzo commercialization

    Transcept: preparing for Intermezzo ® commercialization Therapeutic focus Neuroscience / psychiatry Large markets, Intermezzo ®: middle of the night awakenings unmet needs TO-2061: treatment resistant OCD Commercial U.S. primary care partnership: Purdue Pharma platform Co-promote option 1 yr post In

  4. Slide 4: Intermezzo (zolpidem tartrate sublingual tablet)

    Intermezzo® (zolpidem tartrate sublingual tablet) Proposed indication statement: Intermezzo® is indicated for use as needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep 4

  5. Slide 5: Middle of the night awakening: a major unmet medical need in the insomnia category

    Middle of the night (MOTN) awakening: a major unmet medical need in the insomnia category Large U.S. insomnia market – $2.1 billion (ex-factory)(1) – 78 million new and refill prescriptions(2) Insomnia is an under-treated condition – 11 million patients receive Rx(3) – 4x to 6x more are not diagnose

  6. Slide 6: No product currently indicated for prn treatment at the time of a middle of the night awakening

    No product currently indicated for prn treatment at the time of a middle of the night awakening MOTN awakenings typically do not occur every night 7-8 hr sleep aids (Ambien ®, Ambien CR ®, Lunesta®) require bedtime prophylactic dosing to prevent awakenings An ideal therapeutic would: – Be used only

  7. Slide 7: Intermezzo: anticipated to be the first sleep aid for use in the middle of the night

    Intermezzo ®: anticipated to be the first sleep aid for use in the middle of the night at the time of awakening Sublingual tablet dissolves in ~ 2 minutes Novel formulation pH drives zolpidem base, rapidly absorbed 72% - 86% lower dose than comparable Low dose Ambien CR® dose Sleep lab: sleep onset,

  8. Slide 8: Intermezzo 3.5 mg delivered more zolpidem earlier than a ~3x higher Ambien dose

    Intermezzo ® 3.5 mg delivered more zolpidem earlier than a ~3x higher Ambien ® dose PK comparison study: Intermezzo® 3.5mg vs. Ambien 10mg PO (n=33) 1.5x 4 Intermezzo® 3.5 mg 3 3.0x 2 1 9.6x Ambien® 10 mg 0 0 5 10 15 20 Time (min) 8

  9. Slide 9: Intermezzo commercial opportunity

    Intermezzo® commercial opportunity

  10. Slide 10: Estimating the MOTN market size at branded prices

    Estimating the MOTN market size at branded prices Ohayon, et al., Nocturnal Awakenings in the American 235 M U.S. adults(3) x Ohayon General Population: Prevalence and Consequences MOTN sufferers at least 3x week 35.5% (1) = 83 million …with difficulty returning to sleep 43.0% (1) = 36 …without diff

  11. Slide 11: Commercialization partnership with Purdue Pharma

    Commercialization partnership with Purdue Pharma Leading pain therapeutic franchise 2010 net revenue: ~$2.4 billion Branded products include: OxyContin®, MSContin®, Dilaudid®, Butrans® Sales force of >500 field reps calling on primary care physicians and high prescribing specialists High value pain

  12. Slide 12: Commercialization agreement: key Transcept benefits

    Commercialization agreement: key Transcept benefits Co-promote option: foundation for a commercial future – Transcept option: co-promote to psychiatrists as early as the first anniversary after Purdue launch Milestone payments – Upfront license fee: $25M received August 2009 – Up to $90M additional

  13. Slide 13: Intermezzo partnership structure enables significant Transcept marketing efficiency

    Intermezzo ® partnership structure enables significant Transcept marketing efficiency Purdue responsibilities – U.S. product launch – Primary care sales and marketing activities – Managed care and formulary placement – Manufacturing and distribution – Post marketing studies, if required – Book reven

  14. Slide 14: Intermezzo managed markets advisory board covering >170M lives

    Intermezzo ® managed markets advisory board with decision makers covering >170M lives Broad formulary access expected Unmet medical need generally recognized by payers – Unique insomnia indication – Low dose used less often – Delivery technology drives rapid bioavailability Tier 3 formulary placemen

  15. Slide 15: Intermezzo NDA resubmission

    Intermezzo® NDA resubmission

  16. Slide 16: July 2011 FDA Complete Response Letter

    July 2011 FDA Complete Response Letter January 2011 NDA resubmission: driving study including comparative analysis, epidemiology study assessing current MOTN use of bedtime hypnotics, and packaging changes FDA newly expressed concern that patients with high outlier zolpidem blood levels may be at ri

  17. Slide 17: Sept 14, 2011 End of Review meeting with FDA

    Sept 14, 2011 End of Review meeting with FDA FDA generally agreed: – Change Intermezzo ® dose for women from 3.5 mg to 1.75 mg; 3.5 mg dose for men unchanged – Intermezzo ® should only be taken if the patient has 4 hours of bedtime remaining. Patients should refrain from driving for at least 1 hour

  18. Slide 18: Sleep lab study: 1.75 mg efficacy in women similar to 3.5 mg efficacy in men

    Sleep lab study: 1.75 mg efficacy in women similar to 3.5 mg efficacy in men Women 1.75 mg (n=58) Men 3.5 mg (n=24) 100 100 90 90 80 80 Intermezzo® 70 70 63% 3.5 mg 60% Intermezzo® 1.75 mg 60 60 50 50 Placebo 40 40 Placebo 30 30 20 20 Baseline 10 10 Baseline 0 0 <10 <20 <30 <10 <20 <30 Latency to pe

  19. Slide 19: New Intermezzo instructions are consistent with current patient behavior

    New Intermezzo ® instructions are consistent with current patient behavior Originally proposed instructions: “Intermezzo ® should only be taken if the patient has 4 hours of bedtime remaining before being active again” Newly proposed instructions: “Intermezzo ® should only be taken if the patient ha

  20. Slide 20: Intermezzo: intellectual property

    Intermezzo®: intellectual property

  21. Slide 21: Intermezzo: two formulation patents issued; method of use patents pending

    Intermezzo ®: two formulation patents issued; method of use patents pending Formulation for transmucosal absorption – Two issued U.S. patents - 7,682,628 and 7,658,945 – Patents expire no sooner than February 2025 – Low dose zolpidem, ~1mg to ~5mg – Formulation with buffer system for transmucosal ab

  22. Slide 22: TO-2061 (low dose ondansetron)

    TO-2061 (low dose ondansetron) Proposed indication: adjunctive therapy in adult patients with obsessive compulsive disorder (OCD) not adequately responsive to currently approved OCD medication 22

  23. Slide 23: Significant unmet medical need: OCD patients not responding adequately to approved medication

    Significant unmet medical need: OCD patients not responding adequately to approved medication Obsessive Compulsive Disorder – Intrusive thoughts and repetitive actions to reduce distress – Affects 1% to 2% of U.S. adult population, 40% to 50% seek treatment – Significantly impacts everyday life acti

  24. Slide 24: Pilot studies: ultra low dose adjunctive ondansetron therapy in SSRI resistant OCD

    Pilot studies: ultra low dose adjunctive ondansetron therapy in SSRI resistant OCD Ondansetron (5-HT3 antagonist approved as Zofran®) – Affects serotonin and dopamine pathways – Typical daily Zofran® doses of 16 mg to 24 mg for nausea and vomiting induced by chemotherapy, radiation therapy and surge

  25. Slide 25: Improvement measured as % decrease over baseline on YBOCS

    Improvement: measured as a % decrease over baseline on the Yale Brown Obsessive Compulsive Scale (YBOCS) Pilot Study B, n=21 0% 0% 10% 10% 20% 20% 30% 30% 40% 40% Responders All patients Non-responders 50% 50% Week Week Week Week Week Week Week Week Week Week Week Week 2 4 6 8 10 12 2 4 6 8 10 12 Al

  26. Slide 26: TO-2061: development overview

    TO-2061 : development overview 505b2 NDA pathway Phase 2 study, n 150, top line data est. late 2012 Intellectual property – Method of use patent application filed, priority date May 19, 2009 – Ondansetron, up to ~1.5 mg/day – Pending claims for treating SSRI resistant OCD with ondansetron augmentati

  27. Slide 27: Financial overview

    Financial overview Transcept PHARMACEUTICALS, INC.

  28. Slide 28: Financial position

    Financial position Cash & investments (6/30/11): $59.6 M Q2 2011 cash burn rate: $ 1.2 M / month Shares outstanding (9/15/11): 13.5 M Options / warrants / other: 3.5 Total: 17.0 M Employees (9/15/11): 18 28

  29. Slide 29: Trademark notices

    Intermezzo ® is a registered trademark of Transcept Pharmaceuticals, Inc. Ambien ® and Ambien CR ® are registered trademarks of sanofi-aventis Lunesta ® is a registered trademark of Sunovion Pharmaceuticals Inc. Zofran ® and Paxil ® are registered trademarks of The GlaxoSmithKline Group of Companies

Transcept Pharmaceuticals — Investor Presentation (September 2011) on 6ix